Rogliani Paola, Calzetta Luigino
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Int J Chron Obstruct Pulmon Dis. 2025 Mar 26;20:831-840. doi: 10.2147/COPD.S504065. eCollection 2025.
Chronic mucus hypersecretion (CMH) in chronic obstructive pulmonary disease (COPD) is associated with severe outcomes, but its impact on mortality across COPD stages is not well understood. This study evaluated the risk of mortality according to mucus plugs and COPD severity.
A subset analysis was performed using secondary unadjusted data from published figures of a study on the COPDGene cohort. Data on mortality rates and mucus plug scores were extracted and classified by the GOLD stages. The mortality risk was calculated based on the number of mucus plugs occluding lung segments and GOLD stage, using calibration curves and best-fitting non-linear regression curve analysis.
The risk of all-cause mortality was significantly increased for GOLD stage 1 patients with ≥1 occluded lung segments (1.48, 95% CI 1.10-1.86; P<0.01) compared to those with no occlusions. Patients with GOLD stage 1 and ≥3 occluded lung segments had a significantly higher mortality risk (1.89, 95% CI 1.43-2.36; P<0.001). No increased mortality risk resulted for patients with 1-2 occluded lung segments and those at GOLD stage 2-4. The number needed to harm analysis indicated that 6 patients with ≥3 occluded segments at GOLD stage 1 were required to observe one death, compared to 26 patients at GOLD stage 4.
The significant mortality risk associated with multiple mucus-plugged segments at GOLD stage 1 supports the potential benefit of thiol-based mucolytic therapy. Targeted interventions to reduce mucus plugs could be crucial in improving survival outcomes for early-stage COPD patients.
慢性阻塞性肺疾病(COPD)中的慢性黏液高分泌(CMH)与严重后果相关,但其对COPD各阶段死亡率的影响尚不清楚。本研究根据黏液栓和COPD严重程度评估了死亡风险。
使用来自COPDGene队列研究已发表数据的二级未调整数据进行亚组分析。提取死亡率和黏液栓评分数据,并根据GOLD分期进行分类。使用校准曲线和最佳拟合非线性回归曲线分析,根据阻塞肺段的黏液栓数量和GOLD分期计算死亡风险。
与无阻塞的GOLD 1期患者相比,有≥1个阻塞肺段的GOLD 1期患者全因死亡风险显著增加(1.48,95%CI 1.10-1.86;P<0.01)。有≥3个阻塞肺段的GOLD 1期患者死亡风险显著更高(1.89,95%CI 1.43-2.36;P<0.001)。有1-2个阻塞肺段的患者和GOLD 2-4期患者的死亡风险没有增加。伤害所需人数分析表明,GOLD 1期有≥3个阻塞段的患者中,观察到1例死亡需要6例患者,而GOLD 4期则需要26例患者。
GOLD 1期多个黏液栓阻塞段与显著的死亡风险相关,这支持了基于硫醇的黏液溶解疗法的潜在益处。针对减少黏液栓的靶向干预对于改善早期COPD患者的生存结局可能至关重要。